Antitumor effect of malaria parasite infection in a murine lewis lung cancer model through induction of innate and adaptive immunity

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Chen, Lili ^a,c   He, Zhengxiang ^a,c   Qin, Li ^a,c   Li, Qinyan ^a,c   Shi, Xibao ^a   Zhao, Siting ^a   Chen, Ling ^a   Zhong, Nanshan ^b   Chen, Xiaoping ^a,c  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; KI 67 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; CANCER VACCINE; CYTOKINE;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; INNATE IMMUNITY; LEWIS CARCINOMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALARIA; METASTASIS; MOUSE; NATURAL KILLER CELL; NICK END LABELING; NONHUMAN; PLASMODIUM YOELII; PROTEIN EXPRESSION; TUMOR IMMUNITY; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELL PROLIFERATION; DENDRITIC CELL; DISEASE MODEL; IMMUNOLOGY; NEOVASCULARIZATION (PATHOLOGY); PARASITE; PARASITOLOGY; PATHOLOGY; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; VASCULARIZATION;

MURINAE; MUS;

ADAPTIVE IMMUNITY; ANIMALS; APOPTOSIS; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MALARIA; MICE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PARASITES; PLASMODIUM YOELII; TH1 CELLS; VACCINES, DNA;

EID: 80052580053     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024407     Document Type: Article

References (59)

1. Jemal A, Siegel R, Xu J, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Gridelli C, Rossi A, Maione P, Ferrara ML, Castaldo V, et al. (2009) Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 14: 909-920.
3. Kakimi K, Nakajima J, Wada H, (2009) Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer 65: 1-8.
4. Kelly RJ, Gulley JL, Giaccone G, (2010) Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality. Clin Lung Cancer 11: 228-237.
5. Van den Heuvel MM, Burgers SA, van Zandwijk N, (2009) Immunotherapy in non-small-cell lung carcinoma: from inflammation to vaccination. Clin Lung Cancer 10: 99-105.
6. Romero P, (2008) Current state of vaccine therapies in non-small-cell lung cancer. Clin. Lung Cancer 9: S28-36.
7. Ho C, Ochsenbein AF, Gautschi O, Davies AM, (2008) Early clinical trial experience with vaccine therapies in non-small-cell lung cancer. Clin Lung Cancer 9: S20-27.
8. Dickson JA, (1979) Hyperthermia in the treatment of cancer. Lancet 1: 202-205.
9. Xu M, Wright WD, Higashikubo R, Roti JR, (1998) Intracellular distribution of hsp70 during long duration moderate hyperthermia. Int J Hyperthermia 14: 211-225.
10. Zhang HG, Mehta K, Cohen P, Guha C, (2008) Hyperthermia on immune regulation: a temperature's story. Cancer Lett 271: 191-204.
11. Paulides MM, Bakker JF, Linthorst M, van der Zee J, Rijnen Z, et al. (2010) The clinical feasibility of deep hyperthermia treatment in the head and neck: new challenges for positioning and temperature measurement. Phys Med Biol 55: 2465-2480.
12. Ing R, Segura M, Thawani N, Tam M, Stevenson MM, (2006) Interaction of mouse dendritic cells and malaria-infected erythrocytes: uptake, maturation, and antigen presentation. J Immunol 176: 441-450.
13. Roetynck S, Baratin M, Johansson S, Lemmers C, Vivier E, et al. (2006) Natural killer cells and malaria. Immunol Rev 214: 251-263.
14. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, et al. (2005) Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther 5: 1303-1315.
15. Woan K, Reddy V, (2007) Potential therapeutic role of natural killer cells in cancer. Expert Opin Biol Ther 7: 17-29.
16. Yoshimoto T, Morishima N, Okumura M, Chiba Y, Xu M, et al. (2009) Interleukins and cancer immunotherapy. Immunotherapy 1: 825-844.
17. Bulk E, Hascher A, Liersch R, Mesters RM, Diederichs S, et al. (2008) Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice. Cancer Res 68: 1896-1904.
18. Steeg PS, (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895-904.
19. Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, et al. (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27: 2542-2552.
20. Ullrich E, Ménard C, Flament C, Terme M, Mignot G, et al. (2008) Dendritic cells and innate defense against tumor cells. Cytokine Growth Factor Rev 19: 79-92.
21. Tanaka H, Yoshizawa H, Yamaguchi Y, Ito K, Kagamu H, et al. (1999) Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells. J Immunol 162: 3574-3582.
22. Berhanu A, Huang J, Alber SM, Watkins SC, Storkus WJ, (2006) Combinational FLt3 ligand and granulocyte macrophage colony-stimulating factor treatment promotes enhanced tumor infiltration by dendritic cells and antitumor CD8(+) T-cell cross-priming but is ineffective as a therapy. Cancer Res 66: 4895-4903.
23. Lamb TJ, Schenk MP, Todryk SM, (2010) How do malaria parasites activate dendritic cells? Future Microbiol 5: 1167-1171.
24. Boissonnas A, Scholer-Dahirel A, Simon-Blancal V, Pace L, Valet F, et al. (2010) Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 32: 266-278.
25. Kurts C, Robinson BW, Knolle PA, (2010) Cross-priming in health and disease. Nat Rev Immunol 10: 403-414.
26. Zimmermann VS, Bondanza A, Monno A, Rovere-Querini P, Corti A, et al. (2004) TNF-alpha coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens. J Immunol 172: 2643-2650.
27. Coban C, Horii T, Akira S, Ishii KJ, (2010) TLR9 and endogenous adjuvants of the whole blood-stage malaria vaccine. Expert Rev Vaccines 9: 775-784.
28. Coban C, Igari Y, Yagi M, Reimer T, Koyama S, et al. (2010) Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe 7: 50-61.
29. Jeon YH, Choi Y, Kim HJ, Kim CW, Jeong JM, et al. (2007) Human sodium iodide symporter gene adjunctive radiotherapy to enhance the preventive effect of hMUC1 DNA vaccine. Int J Cancer 121: 1593-1599.
30. Blattman JN, Greenberg PD, (2004) Cancer immunotherapy: a treatment for the masses. Science 305: 200-205.
31. Alexandroff AB, Jackson AM, O'Donnell MA, James K, (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353: 1689-1694.
32. Issell BF, Valdivieso M, Hersh EM, Richman S, Gutterman JU, et al. (1978) Combination chemoimmunotherapy for extensive non-oat cell lung cancer. Cancer Treat Rep 62: 1059-1063.
33. Hibbs JB Jr, Lambert LH Jr, Remington JS, (1971) Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J Infect Dis 124: 587-592.
34. Fulton AM, Croft W, Dustoor MM, Blazkovec AA, (1979) Mechanisms of Listeria monocytogenes-mediated modulation of tumor growth. Infect Immun 25: 708-716.
35. Yasumoto K, Hanagiri T, Takenoyama M, (2009) Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. Gen Thorac Cardiovasc Surg 57: 449-457.
36. Sardinha LR, D'Império Lima MR, Alvarez JM, (2002) Influence of the polyclonal activation induced by Plasmodium chabaudi on ongoing OVA-specific B- and T-cell responses. Scand J Immunol 56: 408-416.
37. Lima MR, Bandeira A, Falanga P, Freitas AA, Kipnis TL, et al. (1991) Clonal analysis of B lymphocyte responses to Plasmodium chabaudi infection of normal and immunoprotected mice. Int Immunol 3: 1207-1216.
38. Miyakoda M, Kimura D, Yuda M, Chinzei Y, Shibata Y, et al. (2008) Malaria-specific and nonspecific activation of CD8+ T cells during blood stage of Plasmodium berghei infection. J Immunol 181: 1420-1428.
39. Jones KR, Hickling JK, Targett GA, Playfair JH, (1990) Polyclonal in vitro proliferative responses from nonimmune donors to Plasmodium falciparum malaria antigens require UCHL1+ (memory) T cells. Eur J Immunol 20: 307-315.
40. Cockburn IA, Zavala F, (2007) T cell memory in malaria. Curr Opin Immunol 19: 424-429.
41. Donati D, Zhang LP, Chêne A, Chen Q, Flick K, et al. (2004) Identification of a polyclonal B-cell activator in Plasmodium falciparum. Infect Immun 72: 5412-5418.
42. Gowda DC, (2007) TLR-mediated cell signaling by malaria GPIs. Trends Parasitol 23: 596-604.
43. Wood LM, Guirnalda PD, Seavey MM, Paterson Y, (2008) Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors. Immunol Res 42: 233-245.
44. Tangney M, Gahan CG, (2010) Listeria monocytogenes as a vector for anti-cancer therapies. Curr Gene Ther 10: 46-55.
45. Chung MA, Luo Y, O'Donnell M, Rodriguez C, Heber W, et al. (2003) Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine. Cancer Res 63: 1280-1287.
46. Cordeiro RS, Cunha FQ, Filho JA, Flores CA, Vasconcelos HN, et al. (1983) Plasmodium berghei: physiopathological changes during infections in mice. Ann Trop Med Parasitol 77: 455-465.
47. Day JF, Edman JD, (1984) The importance of disease induced changes in mammalian body temperature to mosquito blood feeding. Comp Biochem Physiol A Comp Physiol 77: 447-452.
48. Oh MD, Shin H, Shin D, Kim U, Lee S, et al. (2001) Clinical features of vivax malaria. Am J Trop Med Hyg 65: 143-146.
49. Song HH, O SO, Kim SH, Moon SH, Kim JB, et al. (2003) Clinical features of Plasmodium vivax malaria. Korean J Intern Med 18: 220-224.
50. Greentree LB, (1981) Malariotherapy and cancer. Med Hypotheses 7: 43-49.
51. Kafuko GW, Burkitt DP, (1970) Burkitt's lymphoma and malaria. Int J Cancer 6: 1-9.
52. Odida M, Schmauz R, Lwanga SK, (2002) Grade of malignancy of cervical cancer in regions of Uganda with varying malarial endemicity. Int J Cancer 99: 737-741.
53. Liu F, Hu X, Zimmerman M, Waller JL, Wu P, et al. (2011) TNF-α cooperates with IFN-γ to repress Bcl-xL expression to sensitize metastatic colon carcinoma cells to TRAIL-mediated apoptosis. PLoS One 6: e16241.
54. You J, He Z, Chen L, Deng G, Liu W, et al. (2010) CH05-10, a novel indinavir analog, is a broad-spectrum antitumor agent that induces cell cycle arrest, apoptosis, endoplasmic reticulum stress and autophagy. Cancer Sci 101: 2644-2651.
55. Qiao J, Kottke T, Willmon C, Galivo F, Wongthida P, et al. (2008) Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med 14: 37-44.
56. Wykes MN, Liu XQ, Jiang S, Hirunpetcharat C, Good MF, (2007) Systemic tumor necrosis factor generated during lethal Plasmodium infections impairs dendritic cell function. J Immunol 179: 3982-3987.
57. Jorritsma A, Bins AD, Schumacher TN, Haanen JB, (2008) Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer. Cancer Res 68: 2455-2462.
58. Choudhury HR, Sheikh NA, Bancroft GJ, Katz DR, De Souza JB, (2000) Early nonspecific immune responses and immunity to blood-stage nonlethal Plasmodium yoelii malaria. Infect Immun 68: 6127-6132.
59. Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, et al. (2009) Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res 69: 6256-6264.